“ Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy “ PALO...
“ Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology “ “ Company to host symposium on Advancing Gene...
Kriya anticipates up to 5 programs to enter clinic by the end of 2025 Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
“ Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates “ ...
“ Kriya envisions treating people with NASH using a one-time intramuscular gene therapy enabling continuous expression of native FGF21 “ “ Kriya anticipates advancing its NASH gene therapy candidate...
“ Kriya's therapeutic pipeline addresses a broad range of diseases that collectively affect millions of patients worldwide”with a goal of delivering transformational clinical benefits with one-time...